📢 Exclusive on Gate Square — #PROVE Creative Contest# is Now Live!
CandyDrop × Succinct (PROVE) — Trade to share 200,000 PROVE 👉 https://www.gate.com/announcements/article/46469
Futures Lucky Draw Challenge: Guaranteed 1 PROVE Airdrop per User 👉 https://www.gate.com/announcements/article/46491
🎁 Endless creativity · Rewards keep coming — Post to share 300 PROVE!
📅 Event PeriodAugust 12, 2025, 04:00 – August 17, 2025, 16:00 UTC
📌 How to Participate
1.Publish original content on Gate Square related to PROVE or the above activities (minimum 100 words; any format: analysis, tutorial, creativ
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a "buy" rating.